Compare Adaptive Biotechnologies Corp (ADPT) vs Eaton Corporation plc (ETN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Eaton Corporation plc — how do they compare? Adaptive Biotechnologies Corp trades at $20.26 (market cap $3.33B), while Eaton Corporation plc trades at $398 (market cap $153.64B). The key difference: Eaton Corporation plc is far larger — about 46.1× Adaptive Biotechnologies Corp's market cap, and Eaton Corporation plc pays a 1.11% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | ETN | |
|---|---|---|
Market Cap | $3.33B | $153.64B |
Sector | Health | Technology |
52-Week High | $22.37 | $435.78 |
52-Week Low | $10.24 | $315.82 |
Enterprise Value | $3.19B | $174.72B |
Dividend Yield | — | 1.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Eaton (ETN) trades at $413.42, up 3.74% with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 20.87% ROE and 13.99% net margin, though valuation ratios like a 40.45 P/E are elevated. Recent news highlights sustainability investments and AI infrastructure opportunities, while analyst consensus remains strongly positive with a $449.50 price target.
Outlook is supported by earnings momentum and sector tailwinds, but high valuation and competitive pressures pose risks. The absence of sell ratings and institutional bullishness suggest upside potential, though investors should weigh growth against premium multiples in a volatile market environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Eaton Corporation plc
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →
